Stock AnalizPraxis Precision Medicines, Inc. PRAX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Praxis Precision Medicines, Inc. (PRAX) is a healthcare company listed in the US with a market value of about $9.2B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -96%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $9M | $2M | $0 | — | — | — |
| Net income | -$303M | -$183M | -$123M | -$214M | -$167M | -$62M | -$36M |
| Free cash flow | -$249M | -$132M | -$111M | -$185M | -$126M | -$53M | -$34M |
| EPS (diluted) | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-59.10 | $-117.90 | $-399.00 |
| Net margin | — | -2137.5% | -5037.9% | — | — | — | — |
| ROIC | -29.3% | -35.4% | -138.3% | -213.4% | -65.6% | -21.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $683.42, 108% above the current price; targets range from $189.00 to $1201.00; the consensus rating is “Strong buy”; expected EPS is $-13.37 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Praxis Precision Medicines pay a dividend?
Not currently.
Is Praxis Precision Medicines a good stock to buy?
We do not give buy or sell advice. Praxis Precision Medicines scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.